UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 33

Sortiert nach

Les géosciences au service de l’archéologie agraire. Une étude de cas sur les rideaux de culture de Goldbach (68)

Archimède : archéologie et histoire ancienne, 2020-06 (7), p.205-216

2020

Volltextzugriff (PDF)

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

Journal of clinical oncology, 2016-04, Vol.34 (10), p.1034-1042

2016

Volltextzugriff (PDF)

A modified R-type bacteriocin specifically targeting Clostridium difficile prevents colonization of mice without affecting gut microbiota diversity

mBio, 2015-03, Vol.6 (2)

2015

Volltextzugriff (PDF)

Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial)

NPJ breast cancer, 2024-01, Vol.10 (1), p.4-4, Article 4

2024

Volltextzugriff (PDF)

Long-Term Effects of Laparoscopic Sleeve Gastrectomy and Roux-en-Y Gastric Bypass on Body Composition and Bone Mass Density

Obesity facts, 2021-03, Vol.14 (1), p.131-140

2021

Volltextzugriff (PDF)

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

The lancet oncology, 2019-08, Vol.20 (8), p.1148-1159

2019

Volltextzugriff (PDF)

Effects of kappa opioids in the inflamed rat colon

Pain (Amsterdam), 1999-02, Vol.79 (2), p.175-185

1999

Volltextzugriff (PDF)

Colorectal-Cancer Incidence and Mortality with Screening Flexible Sigmoidoscopy

The New England journal of medicine, 2012-06, Vol.366 (25), p.2345-2357

2012

Volltextzugriff (PDF)

Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial

JAMA : the journal of the American Medical Association, 2011-06, Vol.305 (22), p.2295

2011

Volltextzugriff (PDF)

Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes

The New England journal of medicine, 2015-08, Vol.373 (7), p.610-620

2015

Volltextzugriff (PDF)

Mortality Results from a Randomized Prostate-Cancer Screening Trial

The New England journal of medicine, 2009-03, Vol.360 (13), p.1310-1319

2009

Volltextzugriff (PDF)

A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease

The New England journal of medicine, 2009-06, Vol.360 (24), p.2503-2515

2009

Volltextzugriff (PDF)

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials

Journal of clinical oncology, 2015-08, Vol.33 (24), p.2600-2608

2015

Volltextzugriff (PDF)

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation

ESMO open, 2019, Vol.4 (3), p.e000515-e000515, Article e000515

2019

Volltextzugriff (PDF)

SYNTAX Score and Long-Term Outcomes: The BARI-2D Trial

Journal of the American College of Cardiology, 2017-01, Vol.69 (4), p.395-403

2017

Volltextzugriff (PDF)

Recommendations for Collection and Handling of Specimens From Group Breast Cancer Clinical Trials

Journal of clinical oncology, 2008-12, Vol.26 (34), p.5638-5644

2008

Volltextzugriff (PDF)

In utero exposure to Azathioprine in autoimmune disease. Where do we stand?

Autoimmunity reviews, 2020-09, Vol.19 (9), p.102525, Article 102525

2020

Volltextzugriff (PDF)

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023

Cancer chemotherapy and pharmacology, 2013, Vol.71 (1), p.53-62

2013

Volltextzugriff (PDF)

Subclinical ileitis: Diagnostic and performance parameters in a multi-dose mucosal homogenate challenge model

Journal of swine health and production, 2012-05, Vol.20 (3), p.137-141

2012

Volltextzugriff (PDF)

Regional nodal irradiation after breast conserving surgery for HER2-positive breast cancer: Results of a sub analysis from the ALTTO trial

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.604-604

2016

Volltextzugriff (PDF)

SYNTAX Score and Long-Term Outcomes

Journal of the American College of Cardiology, 2017, Vol.69 (4), p.395-403

2017

Volltextzugriff (PDF)

Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort

Journal of the peripheral nervous system, 2009-03, Vol.14 (1), p.1-13

2009

Volltextzugriff (PDF)

Erratum to: Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023

Cancer chemotherapy and pharmacology, 2013-02, Vol.71 (2), p.553-553

2013

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(32)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Les géosciences au service de l’archéologie agraire. Une étude de cas sur les rideaux de culture de Goldbach (68)

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

A modified R-type bacteriocin specifically targeting Clostridium difficile prevents colonization of mice without affecting gut microbiota diversity

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial)

Long-Term Effects of Laparoscopic Sleeve Gastrectomy and Roux-en-Y Gastric Bypass on Body Composition and Bone Mass Density

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

Effects of kappa opioids in the inflamed rat colon

Colorectal-Cancer Incidence and Mortality with Screening Flexible Sigmoidoscopy

Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial

Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes

Mortality Results from a Randomized Prostate-Cancer Screening Trial

A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation

SYNTAX Score and Long-Term Outcomes: The BARI-2D Trial

Recommendations for Collection and Handling of Specimens From Group Breast Cancer Clinical Trials

In utero exposure to Azathioprine in autoimmune disease. Where do we stand?

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023

Subclinical ileitis: Diagnostic and performance parameters in a multi-dose mucosal homogenate challenge model

Regional nodal irradiation after breast conserving surgery for HER2-positive breast cancer: Results of a sub analysis from the ALTTO trial

SYNTAX Score and Long-Term Outcomes

Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort

Erratum to: Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023

First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC)

Suchergebnisse filtern